By Sharon Anderson, President of LMSDR

Every year, Leiomyosarcoma Support & Direct Research Foundation (LMSDR) grants money for ground breaking LMS specific research. When LMSDR started, in 2006, there were almost no researchers studying leiomyosarcoma (LMS.) Then Dr. Matt van de Rijn (our first grant recipient) completed a microarray analysis of about 200 LMS tissue paraffin blocks. These tissue samples were collected by a patient-lead drive with LMSDR.  More studies and discoveries followed. All grants were made possible by the generous donations of the LMS community.

LMSDR’s grants for LMS specific research has resulted in the following research:  

Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcomaLet-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma  by Dr. Eva Hernando of New York University School of Medicine

Discovery of molecular subtypes in leiomyosarcoma through integrated molecular profiling by Matt van de Rijn (Stanford), Chris Coreless (Washington State University) and Jonathon Fletcher (Dana Farber.)

A Role for BRCA1 in Uterine Leiomyosarcoma. Cancer Research by Sandra Orsulic (Cedars Sinai.)

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumor. by Matt van de Rijn (Stanford) 

The Effect of Mir-17-92 Dysregulation in Leiomyosarcoma-Genesis.  by Matt van de Rijn (Stanford)

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma  by Matt van de Rijn (Stanford)

Flipping the script on macrophages in leiomyosarcoma by Matt van de Rijn (Stanford)

CFS1 Expression in nongynological leiomyosarcoma is associated with increased tumor angiogenesis  by Matt van de Rijn (Stanford)

The Study of Three Therapeutic Targets in Leiomyosarcoma by Matt van de Rijn (Stanford)

Engineered SIRPa Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. by Matt van de Rijn (Stanford)

Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals by Matt van de Rijn (Stanford)

Candidate Therapeutic Compounds for Leiomyosarcoma by Matt van de Rijn (Stanford)

Clinically relevant molecular subtypes in leiomyosarcoma by Matt van de Rijn (Stanford)

A role for versican in the development of leiomyosarcoma by Matt van de Rijn (Stanford)

Progressive Loss Of Myogenic Differentiation In Leiomyosarcoma Has Prognostic Value by Matt van de Rijn (Stanford)

And work in progress:

LMS circulating tumor DNA research (liquid biopsy) by Matt van de Rijn (Stanford)

Maximizing Therapeutic Response in Leiomyosarcoma (an International Collaborative with Drs. Fletcher, van de Rijn, Chibon, Bauer and Langenau.

ROR2 and a Potential Target in Leiomyosarcoma by Matt van de Rijn (Stanford)

ART Inhibition in ALT Positive Leiomyosarcoma by Gregory Cote MD (Massachusetts General Hospital.)

Identification of a novel treatment strategy for uterine leiomyosarcoma in genotype defined patient population by Tatiana Omelchenko (Sloan Kettering.)

Exploring Leiomyosarcoma Functional Genomics to Identify Disease Specific Vulnerabilities by Matt Hemming (Dana Farber.)

You can read more about these research projects on our website https://lmsdr.org/grant-awards/

In addition, LMSDR is an all-volunteer foundation – that means we have never had any paid staff. We have very little overhead since we work from our own homes.  This results in your donations going primarily to research.

Your donations are vital to helping us do our work! We are grateful to everyone who has made generous contributions to help us find treatments that will help save lives.

Please join the LMS community and donate HERE